Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study
L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily gluta...
Gespeichert in:
| Veröffentlicht in: | PloS one 2014-11, Vol.9 (11), p.e113366-e113366 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e113366 |
|---|---|
| container_issue | 11 |
| container_start_page | e113366 |
| container_title | PloS one |
| container_volume | 9 |
| creator | Samocha-Bonet, Dorit Chisholm, Donald J Gribble, Fiona M Coster, Adelle C F Carpenter, Kevin H Jones, Graham R D Holst, Jens J Greenfield, Jerry R |
| description | L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.
Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.
HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P |
| doi_str_mv | 10.1371/journal.pone.0113366 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1626535070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A418139471</galeid><doaj_id>oai_doaj_org_article_7e68f438790c40b6a2bbd112a8dded91</doaj_id><sourcerecordid>A418139471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-7751e91145d246e70d1e89da0cfb9b5a0294cef4cb3a486332996950efebad9e3</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7rr6D0QDgujFjPlo0-ZGWBYdBwYW_LoNaXI6k6Ftuk2qjvf-bzMz3WUqeyEtJKTP-56c03OS5DnBc8Jy8m7rhr5V9bxzLcwxIYxx_iA5J4LRGaeYPTzZnyVPvN9inLGC88fJGc1SQhkrzpM_i3qnobEaQVWBDh6p1iCvKgg75Cq0mi3qIajGtoD80HU1NNAGFaxr0U8bNsj1h9UNAXkb1Lq2XbAtim_YdYAoMlaVEMCjLqqi1s8U6mMQ19jfEEOFweyeJo8qVXt4Nq4XybePH75efZqtrhfLq8vVTHNBwyzPMwKCkDQzNOWQY0OgEEZhXZWizBSmItVQpbpkKi04Y1QILjIMFZTKCGAXycujb1c7L8cKekk45RnLcI4jsTwSxqmt7HrbqH4nnbLycOD6tVR9sLoGmQMvqpQVucA6xSVXtCwNIVQVxoARJHq9H6MNZQNGx-R7VU9Mp19au5Fr90OmlAnMi2jwZjTo3c0APsjGeg11rVpww-HeOc5zUoiIvvoHvT-7kVqrmIBtKxfj6r2pvExJQZhI8_295_dQ8TH7RontVtl4PhG8nQgiE-BXWKvBe7n88vn_2evvU_b1CbsBVYeNd7EfY_f5KZgeQd0773uo7opMsNxPy2015H5a5DgtUfbi9AfdiW7Hg_0FWSURig</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1626535070</pqid></control><display><type>article</type><title>Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Samocha-Bonet, Dorit ; Chisholm, Donald J ; Gribble, Fiona M ; Coster, Adelle C F ; Carpenter, Kevin H ; Jones, Graham R D ; Holst, Jens J ; Greenfield, Jerry R</creator><creatorcontrib>Samocha-Bonet, Dorit ; Chisholm, Donald J ; Gribble, Fiona M ; Coster, Adelle C F ; Carpenter, Kevin H ; Jones, Graham R D ; Holst, Jens J ; Greenfield, Jerry R</creatorcontrib><description>L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.
Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.
HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P<0.001) without a significant time-treatment interaction (P = 0.8), but creatinine and estimated glomerular filtration rate (eGFR) were unchanged (P≥0.5). Red blood cells, hemoglobin, hematocrit, and albumin modestly decreased (P≤0.02), without significant time-treatment interactions (P≥0.4). Body weight and plasma electrolytes remained unchanged (P≥0.2).
Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.
ClincalTrials.gov NCT00673894.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0113366</identifier><identifier>PMID: 25412338</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Administration, Oral ; Aged ; Biology and Life Sciences ; Blood ; Blood cells ; Blood glucose ; Body weight ; Care and treatment ; Creatinine ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetes therapy ; Dietary supplements ; Drug Administration Schedule ; Drug Therapy, Combination ; Electrolytic cells ; Endocrinology ; Epidermal growth factor receptors ; Erythrocytes ; Female ; Glomerular filtration rate ; Glucagon ; Glucose ; Glutamine ; Glutamine - administration & dosage ; Glutamine - adverse effects ; Glutamine - therapeutic use ; Glycated Hemoglobin A - metabolism ; Hematocrit ; Hemoglobin ; Hemoglobins ; Hospitals ; Humans ; Hypoglycemic agents ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Insulin ; Male ; Medical research ; Medicine ; Medicine and Health Sciences ; Metabolism ; Metformin ; Metformin - administration & dosage ; Metformin - therapeutic use ; Middle Aged ; Nutrition ; Parenteral nutrition ; Patients ; Peptidase ; Peptides ; Plasma Volume - drug effects ; Randomization ; Safety ; Safety and security measures ; Sitagliptin Phosphate - administration & dosage ; Sitagliptin Phosphate - therapeutic use ; Treatment Outcome ; Type 2 diabetes ; Urea</subject><ispartof>PloS one, 2014-11, Vol.9 (11), p.e113366-e113366</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 Samocha-Bonet et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Samocha-Bonet et al 2014 Samocha-Bonet et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-7751e91145d246e70d1e89da0cfb9b5a0294cef4cb3a486332996950efebad9e3</citedby><cites>FETCH-LOGICAL-c692t-7751e91145d246e70d1e89da0cfb9b5a0294cef4cb3a486332996950efebad9e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239068/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239068/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25412338$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samocha-Bonet, Dorit</creatorcontrib><creatorcontrib>Chisholm, Donald J</creatorcontrib><creatorcontrib>Gribble, Fiona M</creatorcontrib><creatorcontrib>Coster, Adelle C F</creatorcontrib><creatorcontrib>Carpenter, Kevin H</creatorcontrib><creatorcontrib>Jones, Graham R D</creatorcontrib><creatorcontrib>Holst, Jens J</creatorcontrib><creatorcontrib>Greenfield, Jerry R</creatorcontrib><title>Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.
Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.
HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P<0.001) without a significant time-treatment interaction (P = 0.8), but creatinine and estimated glomerular filtration rate (eGFR) were unchanged (P≥0.5). Red blood cells, hemoglobin, hematocrit, and albumin modestly decreased (P≤0.02), without significant time-treatment interactions (P≥0.4). Body weight and plasma electrolytes remained unchanged (P≥0.2).
Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.
ClincalTrials.gov NCT00673894.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Biology and Life Sciences</subject><subject>Blood</subject><subject>Blood cells</subject><subject>Blood glucose</subject><subject>Body weight</subject><subject>Care and treatment</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetes therapy</subject><subject>Dietary supplements</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Electrolytic cells</subject><subject>Endocrinology</subject><subject>Epidermal growth factor receptors</subject><subject>Erythrocytes</subject><subject>Female</subject><subject>Glomerular filtration rate</subject><subject>Glucagon</subject><subject>Glucose</subject><subject>Glutamine</subject><subject>Glutamine - administration & dosage</subject><subject>Glutamine - adverse effects</subject><subject>Glutamine - therapeutic use</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Hematocrit</subject><subject>Hemoglobin</subject><subject>Hemoglobins</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypoglycemic agents</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Metabolism</subject><subject>Metformin</subject><subject>Metformin - administration & dosage</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Nutrition</subject><subject>Parenteral nutrition</subject><subject>Patients</subject><subject>Peptidase</subject><subject>Peptides</subject><subject>Plasma Volume - drug effects</subject><subject>Randomization</subject><subject>Safety</subject><subject>Safety and security measures</subject><subject>Sitagliptin Phosphate - administration & dosage</subject><subject>Sitagliptin Phosphate - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Type 2 diabetes</subject><subject>Urea</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7rr6D0QDgujFjPlo0-ZGWBYdBwYW_LoNaXI6k6Ftuk2qjvf-bzMz3WUqeyEtJKTP-56c03OS5DnBc8Jy8m7rhr5V9bxzLcwxIYxx_iA5J4LRGaeYPTzZnyVPvN9inLGC88fJGc1SQhkrzpM_i3qnobEaQVWBDh6p1iCvKgg75Cq0mi3qIajGtoD80HU1NNAGFaxr0U8bNsj1h9UNAXkb1Lq2XbAtim_YdYAoMlaVEMCjLqqi1s8U6mMQ19jfEEOFweyeJo8qVXt4Nq4XybePH75efZqtrhfLq8vVTHNBwyzPMwKCkDQzNOWQY0OgEEZhXZWizBSmItVQpbpkKi04Y1QILjIMFZTKCGAXycujb1c7L8cKekk45RnLcI4jsTwSxqmt7HrbqH4nnbLycOD6tVR9sLoGmQMvqpQVucA6xSVXtCwNIVQVxoARJHq9H6MNZQNGx-R7VU9Mp19au5Fr90OmlAnMi2jwZjTo3c0APsjGeg11rVpww-HeOc5zUoiIvvoHvT-7kVqrmIBtKxfj6r2pvExJQZhI8_295_dQ8TH7RontVtl4PhG8nQgiE-BXWKvBe7n88vn_2evvU_b1CbsBVYeNd7EfY_f5KZgeQd0773uo7opMsNxPy2015H5a5DgtUfbi9AfdiW7Hg_0FWSURig</recordid><startdate>20141120</startdate><enddate>20141120</enddate><creator>Samocha-Bonet, Dorit</creator><creator>Chisholm, Donald J</creator><creator>Gribble, Fiona M</creator><creator>Coster, Adelle C F</creator><creator>Carpenter, Kevin H</creator><creator>Jones, Graham R D</creator><creator>Holst, Jens J</creator><creator>Greenfield, Jerry R</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20141120</creationdate><title>Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study</title><author>Samocha-Bonet, Dorit ; Chisholm, Donald J ; Gribble, Fiona M ; Coster, Adelle C F ; Carpenter, Kevin H ; Jones, Graham R D ; Holst, Jens J ; Greenfield, Jerry R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-7751e91145d246e70d1e89da0cfb9b5a0294cef4cb3a486332996950efebad9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Biology and Life Sciences</topic><topic>Blood</topic><topic>Blood cells</topic><topic>Blood glucose</topic><topic>Body weight</topic><topic>Care and treatment</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetes therapy</topic><topic>Dietary supplements</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Electrolytic cells</topic><topic>Endocrinology</topic><topic>Epidermal growth factor receptors</topic><topic>Erythrocytes</topic><topic>Female</topic><topic>Glomerular filtration rate</topic><topic>Glucagon</topic><topic>Glucose</topic><topic>Glutamine</topic><topic>Glutamine - administration & dosage</topic><topic>Glutamine - adverse effects</topic><topic>Glutamine - therapeutic use</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Hematocrit</topic><topic>Hemoglobin</topic><topic>Hemoglobins</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypoglycemic agents</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Metabolism</topic><topic>Metformin</topic><topic>Metformin - administration & dosage</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Nutrition</topic><topic>Parenteral nutrition</topic><topic>Patients</topic><topic>Peptidase</topic><topic>Peptides</topic><topic>Plasma Volume - drug effects</topic><topic>Randomization</topic><topic>Safety</topic><topic>Safety and security measures</topic><topic>Sitagliptin Phosphate - administration & dosage</topic><topic>Sitagliptin Phosphate - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Type 2 diabetes</topic><topic>Urea</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samocha-Bonet, Dorit</creatorcontrib><creatorcontrib>Chisholm, Donald J</creatorcontrib><creatorcontrib>Gribble, Fiona M</creatorcontrib><creatorcontrib>Coster, Adelle C F</creatorcontrib><creatorcontrib>Carpenter, Kevin H</creatorcontrib><creatorcontrib>Jones, Graham R D</creatorcontrib><creatorcontrib>Holst, Jens J</creatorcontrib><creatorcontrib>Greenfield, Jerry R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samocha-Bonet, Dorit</au><au>Chisholm, Donald J</au><au>Gribble, Fiona M</au><au>Coster, Adelle C F</au><au>Carpenter, Kevin H</au><au>Jones, Graham R D</au><au>Holst, Jens J</au><au>Greenfield, Jerry R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-11-20</date><risdate>2014</risdate><volume>9</volume><issue>11</issue><spage>e113366</spage><epage>e113366</epage><pages>e113366-e113366</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.
Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.
HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P<0.001) without a significant time-treatment interaction (P = 0.8), but creatinine and estimated glomerular filtration rate (eGFR) were unchanged (P≥0.5). Red blood cells, hemoglobin, hematocrit, and albumin modestly decreased (P≤0.02), without significant time-treatment interactions (P≥0.4). Body weight and plasma electrolytes remained unchanged (P≥0.2).
Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.
ClincalTrials.gov NCT00673894.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25412338</pmid><doi>10.1371/journal.pone.0113366</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2014-11, Vol.9 (11), p.e113366-e113366 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1626535070 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Administration, Oral Aged Biology and Life Sciences Blood Blood cells Blood glucose Body weight Care and treatment Creatinine Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - physiopathology Diabetes therapy Dietary supplements Drug Administration Schedule Drug Therapy, Combination Electrolytic cells Endocrinology Epidermal growth factor receptors Erythrocytes Female Glomerular filtration rate Glucagon Glucose Glutamine Glutamine - administration & dosage Glutamine - adverse effects Glutamine - therapeutic use Glycated Hemoglobin A - metabolism Hematocrit Hemoglobin Hemoglobins Hospitals Humans Hypoglycemic agents Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin Male Medical research Medicine Medicine and Health Sciences Metabolism Metformin Metformin - administration & dosage Metformin - therapeutic use Middle Aged Nutrition Parenteral nutrition Patients Peptidase Peptides Plasma Volume - drug effects Randomization Safety Safety and security measures Sitagliptin Phosphate - administration & dosage Sitagliptin Phosphate - therapeutic use Treatment Outcome Type 2 diabetes Urea |
| title | Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A09%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glycemic%20effects%20and%20safety%20of%20L-Glutamine%20supplementation%20with%20or%20without%20sitagliptin%20in%20type%202%20diabetes%20patients-a%20randomized%20study&rft.jtitle=PloS%20one&rft.au=Samocha-Bonet,%20Dorit&rft.date=2014-11-20&rft.volume=9&rft.issue=11&rft.spage=e113366&rft.epage=e113366&rft.pages=e113366-e113366&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0113366&rft_dat=%3Cgale_plos_%3EA418139471%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1626535070&rft_id=info:pmid/25412338&rft_galeid=A418139471&rft_doaj_id=oai_doaj_org_article_7e68f438790c40b6a2bbd112a8dded91&rfr_iscdi=true |